So much bad, so much good, so much old, so much new …
prescription drugs
Posted inHealth and Social Policy
Public Pharma’s Biggest Barrier
California is about to start developing and manufacturing insulin. But is the state too tied up with nonprofit Civica Rx, rather than building its own capacity?
Posted inTAP
The Insulin Shift
Today on TAP: Thanks to Democrats and the American Rescue Plan, insulin prices are going way down for everyone.
Posted inMoney, Politics, and Power
American Kleptocracy Revisited
Our investigative editor’s favorites for 2023
Posted inHealth and Social Policy
On Drug Prices, Biden Opts for Talk Over Action
The administration says it has the ability to employ march-in rights to lower drug prices. When will it actually use them?
Posted inLaw and Justice
Actually, Opioid Victims Love the Sackler Immunity Shields
And other fake news from the Supreme Court’s Purdue Pharma hearing
Posted inHealth and Social Policy
The Next Insulin Scandal
A generic cold medicine available in Europe also turns out to have benefits for Parkinson’s. Biden could prevent the usual effort to patent it and jack up the price.
Posted inHealth and Social Policy
Sanders Seeks Investigation of NIH Licensing Practices
The senator wants the inspector general to probe why the NIH licensed a potentially lucrative cancer drug to an obscure company linked to a former employee.
Posted inHealth and Social Policy
The NIH’s ‘How to Become a Billionaire’ Program
An obscure company affiliated with a former NIH employee is offered the exclusive license for a government-funded cancer drug.